SLC35D1: A Potential Drug Target for Diabetes and Neurodegenerative Disorders

Target Name: SLC35D1

NCBI ID: G23169

SLC35D1: A Potential Drug Target for Diabetes and Neurodegenerative Disorders

SLC35D1 (S35D1_HUMAN) is a protein that is expressed in various tissues of the human body, including the brain, heart, and kidneys. It is a member of the SLC family of transport proteins, which are responsible for transporting a variety of molecules across cell membranes. SLC35D1 has been identified as a potential drug target or biomarker for several diseases, including diabetes, hypertension, and neurodegenerative disorders.

SLC35D1 is expressed in the brain, where it is involved in the transport of various neurotransmitters, including dopamine, serotonin, and ketamine. It is also expressed in the heart, kidneys, and liver, where it is involved in the transport of hormones and other molecules. SLC35D1 is a protein that is composed of 35 amino acid residues, and its molecular weight is approximately 41 kDa.

SLC35D1 has been shown to play a role in several diseases, including diabetes. Diabetes is a chronic metabolic disorder that is characterized by high levels of blood glucose, or hyperglycemia. SLC35D1 has been shown to be involved in the transport of glucose across cell membranes, and it has been suggested as a potential drug target for diabetes.

One of the challenges in the development of new treatments for diabetes is the development of resistance to the disease, which can make the disease more difficult to treat. SLC35D1 has been shown to be involved in the development of insulin resistance, which is a hallmark of type 2 diabetes. Insulin resistance is characterized by decreased sensitivity to insulin, which makes it difficult for the body to use insulin to lower blood glucose levels.

SLC35D1 has also been shown to be involved in the development of neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease. These conditions are characterized by the progressive loss of brain cells, and they are associated with high levels of cognitive impairment and other symptoms. SLC35D1 has been shown to be involved in the transport of neurotransmitters across cell membranes, and it has been suggested as a potential drug target for these conditions.

In addition to its potential role in diabetes and neurodegenerative disorders, SLC35D1 has also been shown to be involved in other conditions, including hypertension and heart failure. SLC35D1 has been shown to be involved in the regulation of blood pressure, and it has been suggested as a potential drug target for hypertension. SLC35D1 has also been shown to be involved in the regulation of heart failure, a condition in which the heart is not able to pump enough blood to meet the body's needs.

SLC35D1 has also been shown to be involved in the regulation of various physiological processes in the body, including cell signaling, metabolism, and inflammation. It has been suggested as a potential drug target for a variety of conditions, including cancer, neuroimmune disorders, and autoimmune disorders.

In conclusion, SLC35D1 (S35D1_HUMAN) is a protein that is expressed in various tissues of the human body, and it has been shown to play a role in the regulation of various physiological processes in the body. Its potential as a drug target or biomarker makes it an attractive target for the development of new treatments for a variety of conditions. Further research is needed to fully understand the role of SLC35D1 in the regulation of physiological processes in the body, and to develop effective treatments for the conditions associated with its dysfunction.

Protein Name: Solute Carrier Family 35 Member D1

Functions: Antiporter that transports nucleotide sugars across the endoplasmic reticulum (ER) membrane in exchange for either their cognate nucleoside monophosphate or another nucleotide sugar (PubMed:16965264, PubMed:17599910, PubMed:31423530). Transports various UDP-sugars including UDP-N-acetyl-alpha-D-glucosamine (UDP-GlcNAc), UDP-N-acetyl-alpha-D-galactosamine (UDP-GalNAc) and UDP-alpha-D-glucuronate (UDP-GlcA), which are used by ER glucosyltransferases as sugar donors for the synthesis of sugar chains of glycoproteins, glycolipids and oligosaccharides (PubMed:11322953, PubMed:16965264, PubMed:17599910, PubMed:31423530, PubMed:17952091). May couple UDP-GlcNAc or UDP-GalNAc efflux to UDP-GlcA influx into the ER lumen that in turn stimulates glucuronidation and subsequent excretion of endobiotics and xenobiotics (PubMed:16965264, PubMed:17599910). Plays a role in chondroitin sulfate biosynthesis, which is important for formation of cartilage extracellular matrix and normal skeletal development (By similarity)

More Common Targets